On (b)(6) 2021 the customer reported a non-reactive covid igg result (access sars-cov-2 igg ii, part number c69057, lot number 922974) was generated on the customer's dxi (unicel dxi 800 access immunoassay analyzer, part number 973100 and serial number (b)(4)) on (b)(6) 2021 for a patient who had been previously vaccinated against covid.The customer did not indicate whether the results were released from the laboratory.The customer did not report a change to patient care of treatment in connection with this event.The customer reported that the patient had been vaccinated against sars-cov-2; initial astrazeneca sars-cov-2 vaccine was administered in early (b)(6) with vaccination series completed in early (b)(6).Customer reported the patient had a reactive covid result using an alternate platform, abbott alinity sars-cov2-igg ii quantitative assay; the result of 3153.9 au/ml was reactive (positive if 50 = au).No hardware errors or issues with other assays were reported in conjunction with this event.System performance indicators such as system check, calibration and quality control were passing within specifications at the time of the event.No issues with sample integrity were reported by the customer.Sample collection, handling and processing information such as sample type, sample volume collected, sample quality, centrifugation time and speed, storage temperature and other information was not provided by the customer.
|
(b)(6).The customer did not provide patient demographics such as weight, ethnicity or race.The access sars-cov-2 igg ii assay was not returned for evaluation.There were no reports of system issues at the time of the event.There was no report of issues with other assays at the time of the event.No hardware errors or flags were reported in conjunction with the event.Sars-cov-2 is an enveloped non-segmented positive-sense rna virus.It has several structural proteins including spike (s), envelope (e), membrane (m) and nucleocapsid (n).The spike protein (s) contains a receptor binding domain (rbd) which is responsible for recognizing the cell surface receptor, angiotensin converting enzyme-2 (ace2).It is found that the rbd of the sars-cov-2 s protein strongly interacts with the human ace2 receptor leading to endocytosis into the host cells and viral replication.The access assay detect antibodies directed against the spike protein, which are more likely to neutralize the virus.Different vaccines were placed on the market and do not elicit the same immune response.Additionally, the access sars-cov-2 igg ii assay is not currently labelled for vaccine response detection and is not currently standardized against the international standard.The performances of the access sars-cov-2 igg ii assay have not been established in individuals that have received a covid-19 vaccine.In conclusion, the cause of this event cannot be determined with the available information.
|